Contributor content
Presentation
Gene therapy for short QT syndrome type 1 (SQT1): a proof-of-concept efficacy trial in transgenic SQT1 rabbits
Presentation
In vivo KCNH2-suppression-replacement gene therapy attenuates the pathogenic phenotype in transgenic rabbits with short QT syndrome type 1
Presentation


